 |
Features & Ingredients
- ABOUT THE RESEARCHER
- Gary S. Goldman holds a Ph.D. in Computer Science from Pacific Western University in Los Angeles and graduated with honors in 1977 from California State University, Fullerton (CSUF). Dr. Goldman served for eight years (from January, 1995 until his resignation in October, 2002) as Research Analyst for the Varicella Active Surveillance Project in Antelope Valley, in a cooperative project with the Centers for Disease Control and Prevention (CDC, Atlanta, GA). In his resignation, he stated, “Whenever research data and information concerning potential adverse effects associated with a vaccine used in human populations are suppressed and/or misrepresented by health authorities, not only is this most disturbing, this goes against all accepted scientific norms. It also dangerously compromises scientists’ professional ethics.”
- Dr. Goldman’s authoritative expertise on varicella and herpes zoster is testified to by his serving on the editorial board of several prominent medical journals as well as his publication of nine medical journal articles on chickenpox and shingles between 2002 and 2006:
- [1] "Varicella disease after introduction of varicella vaccine in the United States", 1995-2000. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Xhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. Journal of the American Medical Association 2002; 287(5):606-11.
- [2] "Second varicella infections: are they more common than previously thought?" Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, Mascola L, Wharton M. Pediatrics 2002 Jun.; 109(6):1068-73.
- [3] "Varicella susceptibility and incidence of herpes-zoster among children and adolescents in a community under active surveillance". Goldman G. Vaccine 2003 Oct. 1; 21 (27-30):4238-42.
- [4] "Incidence of herpes-zoster among children and adolescents in a community with moderate varicella vaccination coverage". Goldman G. Vaccine 2003 Oct.1; 21 (27-30):4243-49.
- [5] "Using capture-recapture methods to assess varicella incidence in a community under active surveillance". Goldman G. Vaccine 2003 Oct 1; 21 (27-30):4250-55.
- [6] "Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology". Goldman G. Vaccine 2005 May; 23(25):3349-55.
- [7] "Response to Letter to Editor by Jumaan: Goldman’s role in the Varicella Active Surveillance Project". Goldman GS. Vaccine 2004 Sep. 3; 22(25-26):3232-6.
- [8] "Universal varicella vaccination: Efficacy trends and effect on herpes-zoster". Goldman GS. International Journal of Toxicology 2005 July-Aug.; 24(4):205-13.
- [9] "The Case against Universal Varicella Vaccination". [Commentary] Goldman GS. International Journal of Toxicology 2006 Sept.-Oct.; 26(5):31
|
|